Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences (NASDAQ: MRVI) plans to announce third-quarter financial and operating results after market close on November 4, 2026.
The company will host a conference call and webcast that day at 2:00 p.m. PT / 5:00 p.m. ET. A live or archived webcast will be available in the Investors section of its website.
Maravai LifeSciences (NASDAQ: MRVI) subsidiary TriLink BioTechnologies has secured an additional Chinese patent covering CleanCap compounds and pharmaceutical compositions incorporating CleanCap-capped RNA.
Granted by the China National Intellectual Property Administration, patent ZL202511246658.5 protects the cap analog compounds themselves, RNA molecules containing them, cells containing those RNA molecules, and pharmaceutical compositions, including drug products. It is TriLink's second CleanCap patent granted in China within months. The earlier patent, ZL202511246578.X, covers methods of synthesizing capped RNA; the new grant adds protection for the molecular structures and compositions rather than only the manufacturing methods.
Maravai LifeSciences (NASDAQ: MRVI) reported second quarter 2026 revenue of $51.4 million, up 8.5% year over year. Segment revenue was $34.7 million for TriLink (up 11.5%) and $16.8 million for Cygnus (up 2.8%). Net loss narrowed to $(21.6) million from $(69.8) million, while Adjusted EBITDA turned positive at $8.7 million versus $(10.4) million a year earlier.
For the first half of 2026, revenue rose 24.4% to $117.3 million, with TriLink up 37.3% and Cygnus up 2.1%. Six‑month net loss improved to $(28.0) million and Adjusted EBITDA reached $29.0 million. Maravai reiterated 2026 revenue guidance of $205–$215 million and raised its 2026 Adjusted EBITDA outlook to $33–$35 million. The company highlighted the opening of a GMP enzyme manufacturing facility and rapid ModTail adoption to over 125 active customers.
Maravai LifeSciences (NASDAQ: MRVI) will release its second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The company will host an earnings conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET, with live and archived access available in the Investors section of its website.
Maravai LifeSciences (NASDAQ: MRVI), through its subsidiary TriLink BioTechnologies, has received a new patent from the China National Intellectual Property Administration (CNIPA), patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules with its CleanCap® capping analogs, including the latest M6 analog.
The allowed claims cover co-transcriptional RNA synthesis using trimer or tetramer capping structures, strengthening TriLink’s intellectual property in China. CleanCap® technology is also patented in major markets including the US, EU, Australia, Japan, Korea, Hong Kong, and Canada, and has been used in approved COVID-19 mRNA and saRNA vaccines and broader RNA therapeutic programs.
TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), opened a purpose-built GMP enzyme manufacturing facility in Jupiter, Florida, enabling coordinated supply of key RNA and IVT raw materials from research through commercial production.
The site is already shipping commercial GMP enzyme batches, led by GMP CleanScribe™ RNA Polymerase, which TriLink reports can reduce dsRNA formation by up to 85% versus standard Wild-type T7 enzymes.
Maravai LifeSciences (NASDAQ: MRVI) refinanced its credit agreement, securing a $150 million term loan and a $30 million revolving credit facility. About $98.5 million of cash plus the new term loan were used to prepay debt due October 2027.
The transaction lowers long-term debt from $242.9 million to $150.0 million in principal and extends the term loan maturity to June 2032, while preserving additional liquidity through the revolving facility to support strategic and growth initiatives.
Maravai LifeSciences (NASDAQ: MRVI) will participate in the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 12:50 p.m. Eastern Time. CFO Raj Asarpota will join a fireside chat, with a live and archived webcast available on the company’s investor relations website.
Maravai LifeSciences (NASDAQ: MRVI) reported Q1 2026 results: revenue $65.8M (+40.5% YoY), net loss $(6.4)M, and Adjusted EBITDA $20.3M. TriLink revenue was $47.5M (+65.1%) including $14.3M of CleanCap COVID orders; TriLink base (ex-COVID) grew 15.4% YoY. Free cash flow returned to positive at $4.2M. Management raised full‑year 2026 guidance to $205–215M revenue and $30–32M Adjusted EBITDA.
Maravai LifeSciences (NASDAQ: MRVI) will report Q1 2026 financial and operating results after market close on Thursday, May 7, 2026 and will host a conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join by telephone (dial-in numbers provided) or via live and archived webcast on the company's Investors website.